Study of NM8074 in Adult Soliris-Treated PNH Patients
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label study designed to evaluate the safety, efficacy, and
immunogenicity of NM8074 in PNH patients undergoing complement-inhibitor therapy with
Soliris.